Adbiotech Co. Ltd.
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.
Adbiotech Co. Ltd. (179530) - Net Assets
Latest net assets as of September 2025: ₩14.44 Million KRW
Based on the latest financial reports, Adbiotech Co. Ltd. (179530) has net assets worth ₩14.44 Million KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩27.51 Billion) and total liabilities (₩27.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩14.44 Million |
| % of Total Assets | 0.05% |
| Annual Growth Rate | 4.37% |
| 5-Year Change | -48.14% |
| 10-Year Change | N/A |
| Growth Volatility | 81.92 |
Adbiotech Co. Ltd. - Net Assets Trend (2014–2024)
This chart illustrates how Adbiotech Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adbiotech Co. Ltd. (2014–2024)
The table below shows the annual net assets of Adbiotech Co. Ltd. from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩4.84 Billion | -55.41% |
| 2023-12-31 | ₩10.85 Billion | -32.98% |
| 2022-12-31 | ₩16.19 Billion | +217.01% |
| 2021-12-31 | ₩5.11 Billion | -45.26% |
| 2020-12-31 | ₩9.33 Billion | +33.50% |
| 2019-12-31 | ₩6.99 Billion | +54.40% |
| 2018-12-31 | ₩4.53 Billion | -1.64% |
| 2017-12-31 | ₩4.60 Billion | +45.88% |
| 2014-12-31 | ₩3.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adbiotech Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2083.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩4.57 Billion | 94.49% |
| Other Components | ₩24.65 Billion | 509.59% |
| Total Equity | ₩4.84 Billion | 100.00% |
Adbiotech Co. Ltd. Competitors by Market Cap
The table below lists competitors of Adbiotech Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reef Casino Trust
AU:RCT
|
$6.84 Million |
|
Asuransi Kresna Mitra Tbk PT
JK:ASMI
|
$6.84 Million |
|
Nuburu Inc
PINK:BURUW
|
$6.85 Million |
|
Luzhou Xinglu Water (Group) Co., Ltd.
F:2LX
|
$6.85 Million |
|
Naphtha
TA:NFTA
|
$6.84 Million |
|
AI/ML Innovations Inc
OTCQB:AIMLF
|
$6.84 Million |
|
Crest Builder Holdings Bhd
KLSE:8591
|
$6.84 Million |
|
New Frontier Minerals Ltd
AU:NFM
|
$6.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adbiotech Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,392,538,850 to 4,836,799,170, a change of -8,555,739,680 (-63.9%).
- Net loss of 7,952,048,120 reduced equity.
- Other factors decreased equity by 603,691,560.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.95 Billion | -164.41% |
| Other Changes | ₩-603.69 Million | -12.48% |
| Total Change | ₩- | -63.88% |
Book Value vs Market Value Analysis
This analysis compares Adbiotech Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.48x to 3.32x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | ₩709.68 | ₩1757.00 | x |
| 2017-12-31 | ₩1095.42 | ₩1757.00 | x |
| 2018-12-31 | ₩1063.84 | ₩1757.00 | x |
| 2019-12-31 | ₩1415.13 | ₩1757.00 | x |
| 2020-12-31 | ₩1226.64 | ₩1757.00 | x |
| 2021-12-31 | ₩663.67 | ₩1757.00 | x |
| 2022-12-31 | ₩1770.73 | ₩1757.00 | x |
| 2023-12-31 | ₩1465.20 | ₩1757.00 | x |
| 2024-12-31 | ₩529.16 | ₩1757.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adbiotech Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -164.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -71.41%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 4.77x
- Recent ROE (-164.41%) is below the historical average (-42.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -24.95% | -16.00% | 0.49x | 3.16x | ₩-1.10 Billion |
| 2017 | 6.15% | 4.11% | 0.66x | 2.27x | ₩-177.03 Million |
| 2018 | -73.15% | -44.52% | 0.77x | 2.14x | ₩-3.76 Billion |
| 2019 | 5.55% | 4.03% | 0.85x | 1.63x | ₩-311.19 Million |
| 2020 | -78.75% | -74.83% | 0.52x | 2.02x | ₩-8.28 Billion |
| 2021 | -52.19% | -22.50% | 0.56x | 4.11x | ₩-3.18 Billion |
| 2022 | 16.66% | 25.36% | 0.34x | 1.92x | ₩1.08 Billion |
| 2023 | -21.38% | -27.34% | 0.37x | 2.10x | ₩-4.20 Billion |
| 2024 | -164.41% | -71.41% | 0.48x | 4.77x | ₩-8.44 Billion |
Industry Comparison
This section compares Adbiotech Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adbiotech Co. Ltd. (179530) | ₩14.44 Million | -24.95% | 1903.92x | $6.84 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |